sar
studi
azetidinecontain
dipeptid
prototyp
inhibitor
hcmv
describ
three
seri
structur
modifi
analogu
involv
substitut
nand
cterminu
ctermin
sidechain
synthes
evalu
antivir
activ
aliphat
substitu
ccarboxamid
group
aliphat
ctermin
sidechain
well
benzyloxycarbonyl
moieti
nterminu
absolut
requir
antihcmv
activ
conform
restrict
induc
residu
dipeptid
deriv
identifi
h
nmr
ctype
revers
turn
seem
influenc
activ
molecul
human
cytomegaloviru
hcmv
preval
bherpesviru
caus
seriou
lifethreaten
diseas
immunolog
immatur
immunocompromis
individu
like
neonat
aid
patient
transplant
recipi
moreov
infect
hcmv
suggest
associ
certain
vascular
diseas
atherosclerosi
restenosi
etc
current
antivir
agent
approv
hcmv
infect
ganciclovir
acyclovir
val
prodrug
valganciclovir
valacyclovir
cidofovir
foscarnet
antisens
rna
fomivirsen
demonstr
gener
suboptim
efficaci
safeti
profil
moreov
drug
suffer
unfavour
pharmacokinet
properti
antivir
drug
resist
emerg
therefor
still
need
effect
safe
therapeut
agent
hcmv
diseas
antihcmv
approv
drug
except
fomivirsen
inhibitor
viral
dna
polymeras
compound
differ
mechan
action
also
appear
among
lribos
benzimidazol
deriv
maribavir
target
viral
protein
kinas
current
clinic
trial
seri
thiourea
smallmolecul
identifi
potent
antihcmv
agent
inhibit
virion
envelop
fusion
piperidinederiv
compound
describ
first
class
smallmolecul
ligand
chemokin
receptor
thu
also
act
earli
stage
replic
cycl
quit
recent
csulton
deriv
antihcmv
activ
shown
keep
full
antivir
sensit
panel
mutant
hcmv
strain
select
resist
approv
drug
accordingli
suggest
new
mechan
action
still
unclear
hcmv
proteas
essenti
capsid
assembl
viral
matur
consid
attract
target
antihcmv
chemotherapi
sever
structur
divers
inhibitor
describ
includ
activ
carbonyl
group
mechanismbas
inhibitor
coval
interact
ser
residu
within
enzym
activ
site
among
latter
other
discov
simpl
small
blactam
deriv
antihcmv
activ
case
simpl
delet
carbonyl
group
blactam
ring
result
correspond
azetidin
deriv
behav
noncoval
inhibitor
hcmv
replic
preliminari
structureact
relationship
studi
suggest
import
certain
hydrophob
environ
carboxyl
posit
azetidin
ring
moreov
within
seri
ctermin
carboxamid
deriv
show
restrict
rotat
around
bond
due
stabil
cturnlik
fold
conform
investig
structur
conform
issu
within
azetidin
deriv
determin
interest
antivir
agent
initi
program
direct
modif
compound
select
prototyp
fig
end
divers
substitu
builtin
ctermin
carboxamid
moieti
amino
acid
sidechain
differ
charact
select
ctermin
residu
b
ntermin
benzyloxycarbonyl
group
replac
differ
urethan
acyl
urea
moieti
contain
aromat
group
c
paper
deal
solutionsolidphas
synthesi
conform
analysi
nmr
biolog
assay
compound
result
three
indic
seri
ac
azetidinecontain
dipeptid
increas
hydrophob
charact
compound
differ
alkyl
group
incorpor
ctermin
carboxamid
gener
deriv
seri
prepar
compound
achiev
coupl
azetidin
correspond
lalanyl
carboxamid
standard
solut
methodolog
scheme
final
compound
obtain
good
yield
mixtur
two
diastereoisom
could
chromatograph
resolv
sinc
start
azetidin
r
enantiomer
mixtur
major
compon
mixtur
assign
sdiastereoisom
understand
role
ctermin
amino
acid
sidechain
dala
phe
val
leu
lysand
glubear
deriv
design
seri
b
solidphas
synthet
methodolog
employ
rinkamid
polystyren
resin
insolubl
matrix
use
prepar
compound
scheme
remov
fmocprotect
group
commerci
resin
correspond
fmocxaaoh
amino
acid
coupl
use
dichobt
afford
intermedi
similar
procedur
follow
subsequ
incorpor
azetidin
result
resinbound
azetidinecontain
dipeptid
final
detach
polymer
support
treatment
tfah
otip
cleavag
cocktail
previou
seri
compound
obtain
excel
yield
mixtur
two
diastereoisom
separ
column
chromatographi
configur
assign
previous
indic
analogu
take
account
inact
nmethoxycarbonylsubstitut
analogu
suggest
role
aromat
phenyl
ring
zgroup
differ
arcontain
urethan
acyl
urea
group
envisag
substitu
posit
azetidin
moieti
seri
c
good
result
synthesi
compound
prompt
us
appli
similar
solidphas
approach
prepar
third
seri
deriv
scheme
case
fmoclala
resin
deprotect
coupl
fmocazetidin
deriv
provid
key
intermedi
unfortun
coupl
step
difficult
despit
repeat
kaiser
test
indic
incomplet
incorpor
direct
cleavag
afford
purif
fmocazetidin
dipeptid
remov
fmocprotec
group
follow
reaction
differ
chloroform
acylor
sulfonylchlorid
presenc
propylen
oxid
gave
deriv
cleavag
altern
treatment
isocyan
follow
exposur
cleavag
cocktail
allow
prepar
urea
analogu
case
major
sdiastereoisom
mixtur
isol
enough
puriti
biolog
assay
defici
coupl
azetidin
deriv
could
respons
format
complex
reaction
crude
make
purif
step
difficult
prepar
compound
characteris
standard
analyt
spectroscop
method
h
nmr
spectra
alway
show
cistran
rotam
around
con
bond
fluctuat
ci
conform
cdcl
increas
dmsod
previou
work
antihcmv
nbenzyloxycarbonylazetidin
found
activ
deriv
low
conform
flexibl
due
format
revers
cturn
stabil
intramolecular
hydrogen
bond
z
carbonyl
group
nh
proton
recent
studi
azetidinecontain
model
peptid
confirm
nonproteinogen
amino
acid
valuabl
cturn
induc
ascertain
whether
particular
fold
conform
could
play
role
antivir
activ
new
prepar
compound
chemic
shift
temperatur
coeffici
amid
proton
evalu
cdcl
chemic
shift
valu
anh
amid
proton
major
transrotam
alway
ppm
variat
chang
dmsod
small
ppm
case
suggest
particip
proton
intramolecular
stabl
hydrogen
bond
protect
solvent
influenc
contrari
ctermin
conh
conhr
amid
proton
show
chemic
shift
rang
ppm
cdcl
chang
solvent
result
import
fluctuat
valu
indic
solvent
exposur
normal
ppm
see
tabl
supplementari
data
variat
amid
proton
chemic
shift
temperatur
measur
dmsod
compound
calcul
temperatur
coeffici
record
tabl
establish
small
peptid
valu
ppbk
absolut
valu
indic
solventprotect
nh
probabl
implic
hydrogen
bond
valu
ppbk
indic
access
solvent
nonhydrogenbond
state
ppbk
rang
uncertainti
shown
tabl
compound
show
dddt
valu
anh
amid
proton
ppbk
small
number
valu
conclus
data
point
toward
stabil
cturn
structur
format
intramolecular
hydrogen
bond
implic
anh
amid
proton
contrast
temperatur
coeffici
ctermin
amid
proton
larg
enough
indic
total
access
solvent
except
compound
r
dddt
valu
amid
proton
suggest
either
coexist
two
conform
state
band
cturn
singl
doubleturn
conform
azetidinederiv
dipeptid
three
seri
ac
evalu
abil
inhibit
replic
hcmv
vitro
result
compar
refer
compound
commerci
drug
ganciclovir
tabl
shown
tabl
deriv
r
tertbutyl
isobutyl
group
ctermin
amid
retain
antihcmv
activ
ec
valu
compar
model
dipeptid
benzyland
cyclohexylsubstitut
analogu
inact
indic
prefer
aliphat
noncycl
substitu
ctermin
posit
lack
antivir
activ
n
ndimethyl
deriv
could
suggest
need
proton
amid
group
possibl
implic
direct
interact
biolog
target
could
explain
inact
estersubstitut
analogu
found
previou
work
although
compound
show
signific
activ
potenti
prefer
sconfigur
could
deduc
comparison
inhibitori
potenc
diastereoisomer
pair
compound
data
obtain
b
c
seri
compound
indic
previou
section
describ
azetidin
dipeptid
adopt
cturnlik
conform
centr
azetidin
residu
explor
extent
structur
characterist
could
import
hcmv
antivir
activ
dipeptid
zphealanh
zphealanh
bu
nonconstrain
analogu
activ
compound
respect
synthes
evalu
amid
proton
peptid
show
temperatur
coeffici
higher
ppbk
absolut
valu
indic
random
coil
conform
therefor
higher
flexibl
azetidinecontain
analogu
dipeptid
unabl
inhibit
replic
hcmv
cell
cultur
tabl
suggest
key
function
azetidin
ring
observ
antivir
activ
direct
role
methylen
group
fourmemb
ring
interact
target
indirect
function
spatial
preorganis
molecul
facilit
interact
function
could
envisag
b
c
defin
tabl
tabl
seri
b
tabl
compound
r
r
deriv
dala
val
leu
respect
maintain
measur
antihcmv
activ
phe
ly
glu
analogu
inact
prefer
aliphat
group
ctermin
residu
observ
howev
neither
increas
aliphat
sidechain
volum
val
leu
vs
ala
chang
configur
ala
residu
succeed
improv
activ
prototyp
activ
compound
b
seri
area
rulealso
somewhat
cytotox
special
dalaand
phecontain
analogu
shown
tabl
prepar
deriv
compound
seri
c
total
inact
lm
except
compound
bear
group
group
consid
conform
restrict
analogu
benzyloxycarbonyl
substitu
present
prototyp
result
suggest
z
group
play
key
role
activ
azetidinederiv
compound
fact
small
chang
incorpor
differ
type
substitu
aromat
phenyl
ring
shorten
benzyl
group
phenyl
replac
urethan
oxygen
atom
ch
nh
led
inact
analogu
compound
inact
hcmv
cytotoxiccytostat
compound
among
three
seri
azetidin
deriv
tabl
assess
hcmv
select
compound
also
evalu
antivir
activ
wide
panel
dna
rna
virus
activ
deriv
hcmv
also
inhibit
replic
varicellazost
viru
vzv
tabl
within
supplementari
data
inact
wide
varieti
dna
rna
virus
subtox
concentr
lm
dual
antivzv
antihcmv
activ
also
describ
nonnucleosid
bicycl
furanopyrimidinederiv
nucleosid
structureact
studi
new
famili
azetidinecontain
dipeptid
inhibitor
hcmv
describ
compound
modifi
ctermin
residu
carboxamid
amino
acid
sidechain
nterminu
easili
synthes
applic
solidphas
solut
methodolog
result
biolog
assay
indic
quit
strict
structur
requir
activ
thu
deriv
aliphat
group
ctermin
residu
either
carboxamid
moieti
sidechain
show
signific
inhibitori
activ
hcmv
replic
cell
cultur
addit
ccarboxamid
group
presenc
hydrogen
atom
absolut
requir
substitut
nterminu
recommend
initi
benzyloxycarbonyl
z
group
best
choic
posit
addit
conform
restrict
induc
revers
turn
ctype
seem
import
activ
sinc
flexibl
dipeptid
analogu
total
inact
sar
studi
need
improv
activ
present
seri
inhibitor
detail
gener
method
complet
h
c
ms
characteris
intermedi
final
compound
see
supplementari
data
azetidin
synthes
accord
previous
report
method
solut
g
mmol
meoh
ml
treat
n
naoh
ml
mmol
reaction
stir
rt
h
solvent
remov
residu
dissolv
water
wash
etoac
aqueou
layer
lyophilis
result
residu
dissolv
mixtur
na
co
dioxan
ml
reaction
cool
solut
clfmoc
g
mmol
dioxan
ml
ad
h
temperatur
allow
rais
rt
reaction
stir
h
water
ad
mixtur
wash
et
organ
layer
acidifi
hcl
ph
extract
etoac
organ
layer
wash
brine
dri
na
solvent
remov
vacuum
residu
purifi
flash
chromatographi
employ
mixtur
etoacch
cl
afford
g
titl
azetidin
gener
procedur
coupl
reaction
solut
correspond
halanr
r
trifluoroacet
mmol
anhydr
thf
treat
azetidin
mg
mmol
bop
g
mmol
et
n
ml
mmol
reaction
stir
overnight
rt
solvent
evapor
result
residu
dissolv
etoac
wash
citric
acid
nahco
brine
organ
layer
dri
na
evapor
afford
residu
purifi
flash
chromatographi
etoacet
ohexan
anal
calcd
c
h
n
c
h
n
found
c
h
n
anal
calcd
c
h
n
c
h
n
found
c
h
n
n
found
c
h
n
gener
procedur
solidphas
coupl
reaction
solut
correspond
fmocxaaoh
mmol
hobt
mmol
anhydr
dmf
ml
treat
dic
mmol
result
mixtur
ad
fmocdeprotect
resin
mmol
h
slow
stir
rt
excess
reagent
elimin
success
wash
dmfdcmdmfdcm
min
afford
intermedi
effici
coupl
reaction
monitor
kaiser
test
similar
procedur
follow
subsequ
incorpor
azetidin
synthesi
nsubstitut
deriv
seri
c
remov
fmoc
group
resin
propylen
oxid
equiv
except
reaction
isocyan
ad
reaction
cool
equiv
correspond
isocyan
chloroform
acylor
sulfonylchlorid
ad
h
slow
stir
room
temperatur
excess
reagent
elimin
success
wash
dmfdcmdmfdcm
min
afford
compound
effici
coupl
reaction
monitor
chloranyl
test
cleavag
reaction
resinbound
compound
cleav
treatment
tfah
otip
cocktail
h
rt
filtrat
kept
resin
wash
dcm
ml
filtrat
contain
final
product
combin
evapor
vacuum
result
residu
dissolv
water
lyophilis
chromatographi
use
solvent
system
indic
case
varicellazost
viru
vzv
vero
sindbi
coxsacki
hela
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
crfk
felin
coronaviru
fipv
felin
herp
viru
mdck
influenza
influenza
b
cell
cultur
confluent
cell
cultur
nearli
confluent
mdck
cell
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
viru
adsorpt
period
residu
viru
remov
cell
cultur
incub
presenc
vari
concentr
fivefold
compound
dilut
test
compound
viral
cytopath
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
minim
cytotox
concentr
mcc
compound
defin
compound
concentr
caus
microscop
visibl
alter
cell
morpholog
methodolog
antihiv
assay
follow
human
cem
cellscm
cell
infect
ccid
hiv
iii
b
rod
ml
seed
well
microtit
plate
contain
appropri
dilut
test
compound
day
incub
hivinduc
cem
giant
cell
format
examin
microscop
confluent
human
embryon
lung
hel
fibroblast
grown
microtit
plate
infect
human
cytomegaloviru
hcmv
strain
davi
pfu
per
well
incub
period
residu
viru
remov
infect
cell
incub
medium
contain
differ
concentr
test
compound
duplic
incub
day
virusinduc
cytopathogen
monitor
microscop
ethanol
fixat
stain
giemsa
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
ec
calcul
graphic
plot
percentag
cytopathogen
function
concentr
compound
cytostat
activ
measur
base
inhibit
hel
cell
growth
hel
cell
seed
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
growth
rel
number
cell
untreat
control
cc
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
cytotox
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
